BioRexis™ develops and produces novel biopharmaceuticals with superior pharmacology using efficient manufacturing systems. Many biopharmaceuticals face difficulties in development and commercialization due to pharmacological issues. For example, many peptides that are currently approved or in development have a very short half-life, requiring both high and frequent dosing.
Unwanted side effects from high peak levels can limit therapeutic benefit, and frequent trough low levels may narrow application of the particular product. High dosing per patient also places a further burden on already limited manufacturing capacity, driving up the cost of treatment, as in the case of monoclonal antibodies and other high-priced biopharmaceuticals.
BioRexis seeks to solve this problem through a new approach of protein engineering. The goal is to enable cost-efficient production of high value proprietary biopharmaceuticals that provide longer lasting therapeutic benefit and greater safety.